Dr. Caroline K. Kramer is an Endocrinologist and Clinician Scientist
at the Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, and
an Assistant Professor in the Division of Endocrinology and Metabolism,
Medicine, University of Toronto.

Dr. Kramer’s research program focuses on clinical studies aimed at
pinpointing novel factors mediating the interaction between obesity and
the development and progression of metabolic disease. Her program
studies the impact of brown fat on early metabolic disorders by
deep-phenotyping the metabolic changes that take place over time in
people with type 2 diabetes, as well as studies the impact of the drug
empagliflozin on weight loss and pancreatic function in women with
previous gestational diabetes.

She was also co-principal author on a publication describing a new
combination therapy for type 2 diabetes, a finding that has the
potential to change the clinical management of this disease.

In 2016 Dr. Kramer was awarded the Canadian Diabetes Association
Clinician-Scientist Award, for the period 2016-2021. She has also
received the New Investigator Award for Diabetes Research from the
Banting and Best Diabetes Centre (2015-2017). Her research is funded by
CIHR and Heart and Stroke Foundation.

Dr. Kramer obtained her MD degree from the Universidade Federal de
Ciencias da Saude do Porto Alegre, Brazil, and her PhD in Endocrinology
and Epidemiology from the Universidade Federal Do Rio Grande Do Sul and
the University of California San Diego. She undertook post-doctoral
fellowship training at the University of Toronto.

She has published more than 80 primary research publications in
peer-reviewed journals.

At a
Glance

Endocrinologist
and Clinician Scientist at the Leadership Sinai Centre for Diabetes,
Mount Sinai Hospital, and an Assistant Professor in the Division of
Endocrinology and Metabolism, Medicine, University of
Toronto.

Focus
on novel factors mediating interaction between obesity and development
and progression of metabolic disease.

Major Research
Activities

Dr. Kramer’s current research projects involve assessing the impact
of the drug empagliflozin on pancreatic function in women with previous
gestational diabetes, as well as evaluating the effect of brown fat on
metabolic health in type 2 diabetes.